# Study of Tivozanib (AV-951) Plus FOLFOX6 in Subjects With Advanced Colorectal Cancer and Other Gastrointestinal Cancers

> **NCT00660153** · PHASE1 · COMPLETED · sponsor: **AVEO Pharmaceuticals, Inc.** · enrollment: 30 (actual)

## Conditions studied

- Colorectal Cancer
- Gastrointestinal Cancer

## Interventions

- **DRUG:** Tivozanib (AV-951) plus FOLFOX6

## Key facts

- **NCT ID:** NCT00660153
- **Lead sponsor:** AVEO Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2012-06
- **Final completion:** 2012-06
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2012-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00660153

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00660153, "Study of Tivozanib (AV-951) Plus FOLFOX6 in Subjects With Advanced Colorectal Cancer and Other Gastrointestinal Cancers". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00660153. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*